# Top 10 population extracts from lijecnicki vjesnik-139-365_cleaned.json

=== Ranked Population 1 (Extract #14, Patients) — Score: 8 ===
ne crizotinib versus chemo-
Med 2002;346:92–8. therapy in ALK-positive lung cancer. N Engl J Med 2014;371:2167–77.
55. Fossella FV, DeVore R, Kerr RN i sur. Randomized phase III trial of 63. Rittmeyer A, Barlesi F, Waterkamp D i sur. Atezolizumab versus
docetaxel versus vinorelbine or ifosfamide in patients with advanced docetaxel in patients with previously treated non-small-cell lung cancer
non-small-cell lung cancer previously treated with platinum-containing (OAK): a phase 3, open-label, multicentre randomised controlled trial.
chemotherapy regimens. The TAX 320 Non Small Cell Lung Cancer Lancet 2

=== Ranked Population 2 (Extract #15, Patients) — Score: 8 ===
;346:92–8. therapy in ALK-positive lung cancer. N Engl J Med 2014;371:2167–77.
55. Fossella FV, DeVore R, Kerr RN i sur. Randomized phase III trial of 63. Rittmeyer A, Barlesi F, Waterkamp D i sur. Atezolizumab versus
docetaxel versus vinorelbine or ifosfamide in patients with advanced docetaxel in patients with previously treated non-small-cell lung cancer
non-small-cell lung cancer previously treated with platinum-containing (OAK): a phase 3, open-label, multicentre randomised controlled trial.
chemotherapy regimens. The TAX 320 Non Small Cell Lung Cancer Lancet 2017;389:255–65.
Study Group. J Clin

=== Ranked Population 3 (Extract #4, Patients) — Score: 7 ===
čkoj indikaciji (PET nije indiciran, iznimno gemcitabine in stages IB to IIIA non-small cell lung cancer. J Clin On-
prema preporuci multidisciplinarnog tima). col 2012;30:172–8.
8. Gilligan D, Nicolson M, Smith I i sur. Preoperative chemotherapy in
Diseminirana/neresektabilna lokalno uznapredovala patients with resectable non-small cell lung cancer: results of the MRC
bolest – pauza u liječenju, praćenje radi pravodobne LU22/NVALT 2/EORTC 08012 multicentre randomised trial and up-
date of systematic review. Lancet 2007;369:1929–37.
detekcije progresije bolesti
9. NSCLC Meta-analysis Collaborative Gro

=== Ranked Population 4 (Extract #5, Patients) — Score: 7 ===
33. Scagliotti GV, Parikh P, von Pawel J i sur. Phase III study comparing
12. Thomas M, Rübe C, Hoffknecht P i sur. Effect of preoperative chemo- cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemo-
radiation in addition to preoperative chemotherapy: a randomised trial therapy-naive patients with advanced-stage non-small-cell lung cancer.
in stage III non-small cell lung cancer. Lancet Oncol 2008;9:636–48. J Clin Oncol 2008;26:3543–51.
13. Furuse K, Fukuoka M, Kawahara M i sur. Phase III study of concurrent 34. Paz-Ares LG, de Marinis F, Dediu M i sur. PARAMOUNT: final overall
versus s

=== Ranked Population 5 (Extract #7, Patients) — Score: 7 ===
tice Guidelines for diagnosis, treatment
surgery. Ann Thorac Surg 2015;99(2):406–13. and follow-up. Ann Oncol 2016;27:1–27.
20. Douillard JY, Rosell R, De Lena M i sur. Impact of postoperative radia- 41. von Plessen C, Bergman B, Andresen O i sur. Palliative chemotherapy
tion therapy on survival in patients with complete resection and stage I, beyond three courses conveys no survival or consistent quality-of-life
II, or IIIA non-small-cell lungcancer treated with adjuvant chemother- benefi ts in advanced non small-cell lung cancer. Br J Cancer 2006;
apy: the adjuvant Navelbine International Trialist A

=== Ranked Population 6 (Extract #9, Patients) — Score: 7 ===
stage II and IIIA non-small-cell lung cancer: promising long-term Oncol 2007;25:5233–9.
results of the Radiation Therapy Oncology Group–RTOG 9705. J Clin 43. Rosell R, Carceremy E, Gervais R i sur. Erlotinib versus standard che-
Oncol 2005:343;3480–7. motherapy as first-line treatment for European patients with advanced
22. Butts CA, Ding K, Seymour L i sur. Randomized phase III trial of EGFR mutation-positive non-small-cell lung cancer (EURTAC): a
vinorelbine plus cisplatin compared with observation in completely multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;
resected stage IB

=== Ranked Population 7 (Extract #10, Patients) — Score: 7 ===
13:239–46.
analysis of JBR-10. J Clin Oncol 2009;28:29–34. 44. Yang JC, Wu YL, Schuler M i sur. Afatinib versus cisplatin-based che-
23. Douillard JY, Rosell R, De Lena M i sur. Adjuvant vinorelbine plus motherapy for EGFR mutation-positive lung adenocarcinoma (LUX-
cisplatin versus observation in patients with completely resected stage Lung 3 and LUX-Lung 6): analysis of overall survival data from two
IB–IIIA non-small-cell lung cancer (Adjuvant Navelbine International randomised, phase 3 trials. Lancet Oncol 2015;16(2):141–51.
Trialist Association [ANITA]): a randomised controlled trial. Lancet 45.

=== Ranked Population 8 (Extract #11, Patients) — Score: 7 ===
taxel in pulmonary adenocarcinoma. N Engl J Med 2009:3;361(10):
24. Pignon JP, Tribodet H, Scagliotti GV i sur. Lung adjuvant cisplatin
46. Zhou C, Wu JL, Chen G i sur. Erlotinib versus chemotherapy as fi rst-
evaluation: a pooled analysis by the LACE Collaborative Group. J Clin
line treatment for patients with advanced EGFR mutation-positive
Oncol 2008;26:3552–9.
non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre,
25. Strauss GM, Herndon JE 2nd, Maddaus MA i sur. Adjuvant paclitaxel
open-label, randomised, phase 3 study. Lancet Oncol 2011;12(8):
plus carboplatin compared with observatio

=== Ranked Population 9 (Extract #12, Patients) — Score: 7 ===
2011;12(8):
plus carboplatin compared with observation in stage IB non-small-cell
lung cancer: CALGB 9633 with the Cancer and Leukemia Group B,
47. Gridelli C, De Marinis F, Di Maio M i sur. Gefi tinib as fi rst-line treat-
Radiation Therapy Oncology Group, and North Central Cancer Treat-
ment for patients with advanced non-small-cell lung cancer with acti-
ment Group Study Groups. J Clin Oncol 2008;26(31):5043–51.
vating epidermal growth factor receptor mutation: Review of the evi-
26. Sederholm C, Hillerdal G, Lambert K i sur. Phase III trial of gem- dence. Lung Cancer 2011;71(3):249–57.
citabine p

=== Ranked Population 10 (Extract #13, Patients) — Score: 7 ===
8380–8. analysis. J Natl Cancer Inst 2013;105:595–605.
27. Delbaldo C, Michiels S, Syz N i sur. Benefi ts of adding a drug to a single 49. Seto T, Kato T, Nishio M i sur. Erlotinib alone or with bevacizumab as
agent or a 2-agent chemotherapy regimen in advanced non-small-cell fi rst-line therapy in patients with advanced non-squamous non-small-
lung cancer. A meta analysis. JAMA 2004;292:470–84. cell lung cancer harbouring EGFR mutations (JO25567): an open-la-
28. Pujol JL, Barlesi F, Daures JP i sur. Should chemotherapy combina- bel, randomised, multicentre, phase 2 study. Lancet 2014;15:1236–44.
tio

